Transcode Therapeutics, Inc.
RNAZ· Nasdaq
RNAZTranscode Therapeutics, Inc.
Filed Nov 15, 2021 · 10-Q · 46 days after period end · 0001104659-21-139116
| Metric | Q3 2021 | Q3 2020 |
|---|---|---|
| Net Income | -$2.33M | -$1.37M |
| EPS Diluted | -$0.20 | -$0.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Transcode Therapeutics, Inc. · CIK 1829635 · Engraved from SEC EDGAR
ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end
